CClinicalTrials.gg
Status unknownNCT00588926Updated Jan 9, 2008

Changes of the Neuronal Activity in the Subthalamic Nucleus Under Remifentanil Sedation During Stereotactic Electrode Implantation

An interventional study of Remifentanil in Movement Disorders and Effect of Remifentanil, sponsored by Hadassah Medical Organization. Status unknown. Per ClinicalTrials.gov, last updated 2008-01-09.

Sponsored by Hadassah Medical Organization · Not applicable, Interventional, and Basic science

The sponsor has not verified this record recently (last verified Dec 2007), so the status shown — last known as Active, not recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Sex
All
01

Study summary

Deep brain stimulation is commonly used for the treatment of movement disorders. Electrode positioning is usually performed under local anesthesia in fully awake patients. The procedure is uncomfortable to the patients who has to remain motionless during the whole surgery. Previous reports of electrode positioning under general anesthesia was found to be less accurate. This result was probably due to the effect of the anesthetics on the electrical activity of the basal ganglia.

The purpose of this study is to detect possible changes in the electrical activity of the basal ganglia related to remifentanil sedation. electrical activity of single neurons will be recorded before, during and after sedation.

02

Conditions studied

  • Movement Disorders
  • Effect of Remifentanil

Browse trials for

Keywords

  • Deep Brain Stimulation
  • Movement Disorders
  • Remifentanil
  • Sedation
  • Basal Ganglia electrical activity
03

In context

Movement Disorders

320 studies on the registry are indexed under Movement Disorders; 98 are open to participants now.

This study's enrollment of 20 is below the median of 46 across 180 interventional studies indexed under Movement Disorders.

Browse Movement Disorders studies →

Lead sponsor

Hadassah Medical Organization is the lead sponsor of 659 studies on the registry; 54 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients with movement disorder, who are candidates for implantation of deep brain stimulation electrode.

Exclusion criteria

Exclusion Criteria:

  • Suspected difficult intubation
  • history of sleep apnea
  • known allergy for remifentanil
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    A

    The patients get a period of sedation with remifentanil, before, during and after which, the changes in the electrical activity of the Basal Ganglia is recorded.

    Drug: Remifentanil

Interventions

  • DrugRemifentanil

    After the mapping electrode is in situ, recording of baseline electrical activity is done for two-three minutes and an infusion of Remifentanil, 0.1 microgram per kilogram per minute is started. This procedure continues for a few minutes until the patient is sedated and then the infusion is stopped and the patient allowed to recover. The recordings continue during the whole procedure.

06

What researchers measure

Primary outcomes

  1. Electrical activity in the basal ganglia

    Time frame: During the experiment

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Benady A, Zadik S, Eimerl D, Heymann S, Bergman H, Israel Z, Raz A. Sedative drugs modulate the neuronal activity in the subthalamic nucleus of parkinsonian patients. Sci Rep. 2020 Sep 3;10(1):14536. doi: 10.1038/s41598-020-71358-3. PubMed 32884017 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 9, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00588926
Lead sponsor
Hadassah Medical Organization
First posted
Jan 9, 2008
Last update
Jan 9, 2008

Study contacts

Dan Eimerl, MD
principal investigator · Hadassah Medical Organization

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion